Welcome to our dedicated page for MYOMO SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MYOMO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MYOMO's regulatory disclosures and financial reporting.
Myomo, Inc. (MYO) received an amended Schedule 13G/A from Rosalind Advisors, Inc., Rosalind Master Fund L.P. and related individuals, updating their beneficial ownership disclosure. Rosalind Master Fund L.P. is reported as beneficially owning 3,637,886 shares of common stock, representing approximately 9.18% of Myomo’s outstanding common stock, based on 39,607,854 shares outstanding as of July 31, 2026. The group also holds 3,763,258 additional shares issuable upon exercise of pre-funded warrants, but a 9.99% blocker provision prevents exercising these warrants to the extent it would push beneficial ownership above 9.99%. As a result, the reporting persons state they were not able to exercise any of the warrants at the event date. Rosalind Advisors acts as investment advisor to the fund, and Steven Salamon as portfolio manager; both may be deemed beneficial owners but expressly disclaim beneficial ownership of the shares.
MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, reported equity compensation activity involving common stock. On August 7, 2026, he received a grant of 55,149 fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. On the same date, 22,457 shares were disposed of and withheld solely to pay income and other taxes associated with the vesting of these RSUs.
Myomo, Inc. reported that Chief Commercial Officer Micah Mitchell received a grant of 58,409 shares of Common Stock on August 7, 2026 as fully vested Restricted Stock Units paid as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 21,559 shares were withheld and disposed of at $1.42 per share to pay related income and other taxes.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received an equity compensation award. On August 7, 2026, he acquired 146,909 shares of common stock through a grant of fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. Following this award, he holds 1,434,679 shares of common stock directly.
MYOMO, INC. Chief Financial Officer David A. Henry reported equity compensation activity on August 7, 2026. He received a grant of 68,644 shares of Common Stock via fully vested Restricted Stock Units as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 25,310 shares of Common Stock were withheld at $1.42 per share to pay associated income and other taxes related to this RSU vesting.
Myomo, Inc. reported higher revenue and improved margins for the quarter ended June 30, 2026. Revenue grew to $11.7 million from $9.7 million a year earlier, and six‑month revenue rose to $21.8 million from $19.5 million. Gross margin expanded to 72.1% from 62.7% as higher average selling prices and manufacturing efficiencies outweighed increased clinical costs.
Operating expenses were essentially flat at $10.7 million for the quarter, with lower research and development spending and slightly higher general and administrative costs. Operating loss narrowed to $2.3 million from $4.6 million, and net loss improved to $4.0 million, or $0.09 per share, from $4.6 million, or $0.11 per share. For the first half, net loss was $7.0 million versus $8.1 million, while Adjusted EBITDA loss improved to $3.1 million from $6.8 million.
Cash, cash equivalents and short‑term investments totaled $13.5 million at June 30, 2026, with working capital of $13.9 million and operating cash use reduced to $4.1 million in the first half from $11.5 million a year earlier. A $17.5 million term‑loan facility with Avenue adds committed capital but increases interest expense and introduces derivative‑related fair value volatility, and carries covenants on minimum cash, revenue and cash burn. Revenue is driven mainly by direct billing to patients, U.S. and international O&P channels and the MyoConnect referral program, and remains highly dependent on Medicare and other insurance reimbursement, including updated CMS fee schedules for MyoPro devices.
Myomo, Inc. reported second quarter 2026 revenue of $11.7 million, a 21% increase from a year earlier, driven by higher average selling prices and 211 MyoPro units recognized. Gross margin rose to 72.1% from 62.7% as cost reductions and pricing offset higher clinical costs.
Operating expenses were $10.7 million, up less than 1%, leading to an operating loss of $2.3 million versus $4.6 million last year. Net loss was $4.0 million, or $0.09 per share, including a $1.2 million non-cash derivative liability charge, while Adjusted EBITDA loss improved to $0.8 million from $4.0 million. Cash, cash equivalents and short-term investments totaled $13.5 million, with cash used in operating activities reduced to $1.9 million from $8.9 million. Management now expects third quarter 2026 revenue of $11.5 million to $12.0 million and has raised full-year 2026 revenue guidance to $45 million to $47 million, while reiterating expectations for operating leverage and lower second-half cash burn.
Myomo, Inc. Chief Financial Officer David A. Henry reported compensation-related equity transactions in Myomo common stock. On July 10, 2026, he received a grant of 7,840 Restricted Stock Units under a Board-approved program allowing employees to exchange 10% of salary for RSUs, with a grant date fair value of 115% of the salary exchanged; this grant covers three months of salary and vests in full on October 10, 2026. On July 13, 2026, 5,166 shares were disposed of solely to cover income taxes from RSU vesting, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, Henry holds 426,829 shares of Myomo common stock directly.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. Chief Executive Officer Paul R. Gudonis received a grant of 10,454 Restricted Stock Units as equity compensation. The grant is part of a program allowing employees to exchange 10% of salary for RSUs with a grant date fair value of 115% of the salary exchanged, covering three months of salary. These RSUs vest in full on October 10, 2026. Following this grant, Gudonis directly holds 1,287,770 shares of common stock.
Myomo, Inc. insider David Henry filed to sell shares of the company’s common stock. The planned sale involves 5,166 shares to be executed through Morgan Stanley, related to the vesting of Restricted Stock Units on July 9, 2026 covering 12,500 shares. In the prior three months, Henry sold 3,953 shares of Myomo common stock on April 13, 2026 for total proceeds of $2,806.60.